GNX 102
Alternative Names: GNX-102Latest Information Update: 18 Nov 2024
At a glance
- Originator GlycoNex
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Gastrointestinal cancer